Sign In

Frank Torti

Vant Chair at Roivant Sciences

Dr. Frank Torti, currently serving as the Vant Chair at Roivant Sciences, plays a pivotal role as the Chairman of the Board overseeing the public and private companies within the Roivant Pharma family. His responsibilities include managing the various businesses under his purview. Prior to this role, Dr. Torti served as the Vant Investment Chair, leading a group of companies working on about thirty-five investigational drugs across eleven therapeutic areas and orchestrating over fifty clinical trials, which included four successful Phase 3 trials.

Before his tenure at Roivant, Dr. Torti held a position as a partner at New Enterprise Associates (NEA), a prestigious venture capital firm renowned worldwide. At NEA, he collaborated with entrepreneurial companies spanning all stages of growth and played a crucial role in early and growth stage investments. His involvement contributed to the development and commercialization of numerous groundbreaking drugs and medical devices that are integral to contemporary clinical medicine. Some notable companies in his investment portfolio include Annexon Biosciences, Cadence Pharmaceuticals (later acquired by Mallinckrodt plc), and Dermira (NASDAQ: DERM).

Dr. Torti's prior experience also includes work at the Duke University Center for Clinical & Genetic Economics, where he immersed himself in clinical trials research and economic evaluations related to clinical trials. He pursued his education diligently, earning his BA with highest honors as a Morehead Scholar at the University of North Carolina, his MD from the University of North Carolina School of Medicine, and his MBA with distinction from Harvard Business School.

Frank Torti
Add to my network

Location

United States